Everest Lifesciences Company Profile
What is the competitive landscape for EVEREST LIFESCIENCES
EVEREST LIFESCIENCES has three approved drugs.
Summary for Everest Lifesciences
| US Patents: | 0 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for Everest Lifesciences
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Everest Lifesciences | TIZANIDINE HYDROCHLORIDE | tizanidine hydrochloride | TABLET;ORAL | 207170-002 | Jan 26, 2017 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Everest Lifesciences | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 090780-003 | Oct 28, 2015 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Everest Lifesciences | EPLERENONE | eplerenone | TABLET;ORAL | 207842-002 | Oct 25, 2021 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
